Sarasota, FL, Feb. 24, 2017 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled “Myocardial Infarction Treatment Market by Product type (Antiplatelet agents, Glycoprotein IIb/IIIa inhibitors, Antithrombotic agents, Beta-adrenergic blockers, Vasodilators, Angiotensin-Converting Enzyme (ACE) inhibitors, Angiotensin-Receptor blockers, Analgesics, Thrombolytics); Distribution channel (Hospitals, Hospital Pharmacies, Drug Stores and Online Drug Stores); and Region: Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 – 2022”. According to the report, global Myocardial Infarction Treatment Market was valued at approximately USD 1206.5 million in 2016 and is expected to generate revenue of around USD 1726.3 million by end of 2022, growing at a CAGR of around 6.1% between 2017 and 2022.
Myocardial infarction or heart attack is caused due to blockage in the supply of oxygen-rich blood to heart muscles, resulting in permanent heart muscle injury and death of cells. The blockage is due to atherosclerosis, a process in which the plaque (fatty patches) is formed on the inside wall of the coronary artery or one of its smaller branches. If the plaque is ruptured, the blood clot is formed inside the artery blocking the blood flow. People with risk factors such as smoking, dyslipidemia, diabetes are more prone to myocardial infarction.
Browse through 29 Market Tables and 31 Figures spread through 110 Pages and in-depth TOC on “Global Myocardial Infarction Treatment Market: By product, Distribution, Type, Size, Share, Analysis, Segment and Forecast 2016 – 2022”.
Request Free Sample copy of Myocardial Infarction Treatment Market Report @ https://www.zionmarketresearch.com/sample/myocardial-infarction-treatment-market
Global Myocardial Infarction Treatment market is primarily driven by growing incidences of cardiovascular diseases and changes in lifestyle. Other major driving factors are risk factors such as obesity, hypertension, diabetes, reduced physical activity, and rise in a number of smokers. As per WHO, the risk of myocardial infarction is increased in smokers than non-smokers. However, the high price of drug research and development and stringent regulatory policies coupled with high cost of clinical trials may pose the challenge to myocardial infarction treatment market. Nevertheless, increase in acceptance of newer treatment technologies by emerging nations and technology breakthroughs are expected to act new avenues for myocardial infarction treatment market in near future.
The Myocardial Infarction Treatment market is segmented on the basis of different product type including Antiplatelet agents, Glycoprotein IIb/IIIa inhibitors, Antithrombotic agents, Beta-adrenergic blockers, Vasodilators, Angiotensin-Converting Enzyme (ACE) inhibitors, Angiotensin-Receptor blockers, Analgesics, Thrombolytics. Analgesics and antiplatelet agent segments are expected to grow at the fastest rate during the forecast period.
Browse the full "Myocardial Infarction Treatment Market by Product type (Antiplatelet agents, Glycoprotein IIb/IIIa inhibitors, Antithrombotic agents, Beta-adrenergic blockers, Vasodilators, Angiotensin-Converting Enzyme (ACE) inhibitors, Angiotensin-Receptor blockers, Analgesics, Thrombolytics); Distribution channel (Hospitals, Hospital Pharmacies, Drug Stores and Online Drug Stores); and Region: Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 – 2022" report at https://www.zionmarketresearch.com/report/myocardial-infarction-treatment-market
The myocardial infarction treatment market is segmented based on distribution channel into Hospitals, Hospital Pharmacies, Drug Stores and Online Drug Stores. Based on geography, the myocardial infarction treatment market is segmented into North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa.
North America represents developed regional markets for myocardial infarction treatment market and is expected to see the rapid growth in the years to come. The U.S. is by far the leading myocardial infarction treatment market by country in North America. The U.S. market is expected to grow at the highest CAGR during the forecast period. This growth is mainly due to the growing incidences of cardiovascular diseases, obesity, and smokers. Moreover, other risk factors such as hypertension, diabetes, and dyslipidemia are very high in this region which promotes the growth of myocardial infarction treatment market.
Inquire more about this report @ https://www.zionmarketresearch.com/inquiry/myocardial-infarction-treatment-market
Europe was the second largest regional market and is expected to show significant growth in the years to come. This growth is mainly due to increase in a number of patients diagnosed with hypertension. As per WHO, cardiovascular disease (CVD) causes more than half of all deaths across the European region.
Asia-Pacific is expected to witness the fastest growth in the near future. Increasing geriatric population is the major driving factor along with lifestyle changes, physical inactivity and increasing prevalence of diabetes. However increased awareness of such life-threatening diseases may impact the market share.
Request customized copy of report @ https://www.zionmarketresearch.com/custom/1084
Latin America and Middle East & Africa market will be potential market due to increased awareness and adoption of newer myocardial infarction treatment. Thus, all the aforementioned parameters are expected to propel the market growth in this region.
Some of the key players in Myocardial Infarction Treatment market include Bayer, Novartis, Daiichi Sankyo Company Limited, Boehringer Ingelheim GmbH, Sandoz, Astrazeneca, Janssen Biotech, Inc., Merck & Co. Inc., Sanofi, Pfizer Inc. among others.
For more inquiry contact our sales team @ sales@zionmarketresearch.com
This report segments the global Myocardial Infarction Treatment market as follows:
Myocardial Infarction Treatment Market: By Product Type
- Antiplatelet agents
- Glycoprotein IIb/IIIa inhibitors
- Antithrombotic agents
- Beta-adrenergic blockers
- Vasodilators
- Angiotensin-Converting Enzyme (ACE) inhibitors
- Angiotensin-Receptor blockers
- Analgesics
- Thrombolytics
Myocardial Infarction Treatment Market: By Distribution Channel
- Hospitals
- Hospital Pharmacies
- Drug Stores
- Online Drug Stores
Myocardial Infarction Treatment Market: Regional Segment Analysis
- North America
- U.S.
- Europe
- UK
- France
- Germany
- Asia Pacific
- China
- Japan
- India
- Latin America
- Brazil
- The Middle East and Africa
Related Reports:
- Melanoma Drugs Market: https://www.zionmarketresearch.com/report/melanoma-drugs-market
- Osteoporosis Drugs Market: https://www.zionmarketresearch.com/report/osteoporosis-drugs-market
- Medical Device Coatings Market: https://www.zionmarketresearch.com/report/medical-device-coatings-market
- Drug Discovery Informatics Market: https://www.zionmarketresearch.com/report/drug-discovery-informatics-market
- General Anxiety Disorder Market: https://www.zionmarketresearch.com/report/general-anxiety-disorder-market
About Us:
Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Follow Us LinkedIn: https://www.linkedin.com/company/zion-market-research
Follow Us Twitter: https://twitter.com/zion_research